STOCK TITAN
  1. Home
  2. News
  3. PYXS

Pyxis Oncology Inc - PYXS STOCK NEWS

Welcome to our dedicated news page for Pyxis Oncology (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pyxis Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pyxis Oncology's position in the market.

News
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Pyxis Oncology, Inc. granted restricted stock units and stock options to a newly hired employee under the 2022 Inducement Plan. The awards total 39,680 shares and 49,600 shares respectively, with vesting over four years. The stock options have a ten-year term with an exercise price of $4.26, the closing price on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.44%
Tags
none
-
News
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) secures non-dilutive funding through the sale of rights to royalties for Beovu® and another asset to Novartis for $8 million. The company retains rights to three other antibodies in development by Apexigen's licensees. This funding will support the development of their lead Antibody-Drug Conjugate (ADC) asset, PYX-201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.66%
Tags
none
-
News
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
Pyxis Oncology (PYXS) provided a corporate update, reporting progress on PYX-201 and PYX-106 Phase 1 trials, completion of a $50 million private placement, and an expected cash runway into 2H 2026. PYX-201 has shown promising safety profiles with no significant toxicities, and PYX-106 is enrolling subjects for initial results anticipated in 2H 2024. Financially, Pyxis Oncology had $120.8 million in cash and equivalents as of December 31, 2023, with a decrease in research and development expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
earnings
News
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Rhea-AI Summary
Pyxis Oncology, Inc. appoints Dr. Santhosh Palani, a seasoned leader with biopharma experience, to its board of directors. Dr. Palani's expertise will aid in the clinical development of their lead assets, including PYX-201, targeting difficult-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
management
-
News
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) to participate in a fireside chat at Leerink Partners Global Biopharma Conference. Dr. Lara S. Sullivan, President and CEO, will lead the discussion on March 13, 2024. Investors can access the webcast and presentation replay on Pyxis Oncology's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.63%
Tags
conferences
-
News
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) announces the presentation of new preclinical data on PYX-201, a tumor stroma-targeting ADC, at the 2024 AACR Annual Meeting. The data shows potent anti-tumor efficacy across various human cancers in PDX tumor models, with the target EDB+FN overexpressed in multiple solid tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences clinical trial
News
Pyxis Oncology Announces $50 Million Private Placement
Rhea-AI Summary
Pyxis Oncology, Inc. announces a private placement of common stock and pre-funded warrants to raise capital for developing cancer therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.26%
Tags
none
-
News
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Pyxis Oncology, Inc. (Nasdaq: PYXS) reported the approval of a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, under the Pyxis Oncology, Inc. 2022 Inducement Plan. The option to purchase 443,514 shares will vest over four years, with an additional 110,878 shares vesting upon achievement of certain clinical milestones related to data disclosure for PYX-201. The stock options have a ten-year term and an exercise price of $1.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director
Rhea-AI Summary
1910 Genetics (Ticker: 1910) appoints Dr. Shaan C. Gandhi, MD, DPhil, as independent board director, bringing clinical, strategic, and financial leadership. Dr. Gandhi, VP and Head of Strategic Partnerships for Pfizer Ignite, will provide critical clinical perspective and extensive background in biotechnology investing and strategic collaboration to guide the company's trajectory for continued success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
management
News
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Rhea-AI Summary
Pyxis Oncology, Inc. (PYXS) appoints Dr. Ken Kobayashi as Chief Medical Officer, bringing extensive experience in oncology drug development and regulatory affairs. Dr. Kobayashi will lead clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology’s clinical pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
management
Stock PYXS logo
Pyxis Oncology Inc

Nasdaq:PYXS

PYXS Rankings

#3596 Ranked by Market Cap
#3089 Ranked by Stock Gains
N/A Ranked by Dividends

PYXS Stock Data

286.02M
38.49M
20.49%
29.86%
4.65%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About PYXS

pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.